Safety and Efficacy of Intravesical Bacillus Calmette-Guerin Instillations in Steroid Treated and Immunocompromised Patients

Journal of Urology

Volumn 176, Issue 2, 2006, Pages 482-485

  Yossepowitch, Ofer ^a   Eggener, Scott E ^a   Bochner, Bernard H ^a   Donat, S Machele ^a   Herr, Harry W ^a   Dalbagni, Guido ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

bladder; carcinoma in situ; immunocompromised host; Mycobacterium bovis; steroids

Indexed keywords

BCG VACCINE; BECLOMETASONE; FLUNISOLIDE; FLUTICASONE; HYDROCORTISONE; METHYLPREDNISOLONE; PREDNISONE; STEROID; TRIAMCINOLONE ACETONIDE;

ADULT; AGED; ARTICLE; BIOPSY; BLADDER CANCER; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; COMORBIDITY; CONTROLLED STUDY; CYSTOSCOPY; CYTOLOGY; DISEASE COURSE; DISEASE EXACERBATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; FEVER; FOLLOW UP; HIGH RISK PATIENT; HUMAN; IMMUNE DEFICIENCY; IMMUNE SYSTEM; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTE; LYMPHOMA; MALE; MYALGIA; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SUPERFICIAL CANCER; TREATMENT DURATION; TREATMENT RESPONSE;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRAVESICAL; ADULT; AGED; AGED, 80 AND OVER; BCG VACCINE; CARCINOMA IN SITU; FEMALE; HUMANS; IMMUNOCOMPROMISED HOST; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; STEROIDS; URINARY BLADDER NEOPLASMS;

EID: 33745274756     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2006.03.066     Document Type: Article

References (21)

1. Shelley M.D., Court J.B., Kynaston H., Wilt T.J., Fish R.G., and Mason M. Intravesical bacillus Calmette-Guerin in Ta and T1 bladder cancer. Cochrane Database Syst Rev (2000) CD001986
2. Herr H.W., Wartinger D.D., Fair W.R., and Oettgen H.F. Bacillus Calmette-Guerin therapy for superficial bladder cancer. a 10-year followup. J Urol 147 (1992) 1020
3. Sylvester R.J., van der M.A., and Lamm D.L. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer. a meta-analysis of the published results of randomized clinical trials. J Urol 168 (2002) 1964
4. Orihuela E., Herr H.W., Pinsky C.M., and Whitmore Jr. W.F. Toxicity of intravesical BCG and its management in patients with superficial bladder tumors. Cancer 60 (1987) 326
5. Rischmann P., Desgrandchamps F., Malavaud B., and Chopin D.K. BCG intravesical instillations. recommendations for side-effects management. Eur Urol 37 suppl (2000) 33
6. Steg A., Leleu C., Debre B., Boccon-Gibod L., and Sicard D. Systemic bacillus Calmette-Guerin infection, 'BCGitis', in patients treated by intravesical bacillus Calmette-Guerin therapy for bladder cancer. Eur Urol 16 (1989) 161
7. Craddock C.G. Corticosteroid-induced lymphopenia, immunosuppression, and body defense. Ann Intern Med 88 (1978) 564
8. Dukor P., and Dietrich F.M. Characteristic features of immunosuppression by steroids and cytotoxic drugs. Int Arch Allergy Appl Immunol 34 (1968) 32
9. Mahuad C., Bay M.L., Farroni M.A., Bozza V., Del Rey A., Besedovsky H., et al. Cortisol and dehydroepiandrosterone affect the response of peripheral blood mononuclear cells to mycobacterial antigens during tuberculosis. Scand J Immunol 60 (2004) 639
10. Silverstein J., Maclaren N., Riley W., Spillar R., Radjenovic D., and Johnson S. Immunosuppression with azathioprine and prednisone in recent-onset insulin-dependent diabetes mellitus. N Engl J Med 319 (1988) 599
11. Palou J., Angerri O., Segarra J., Caparros J., Guirado L., Diaz J.M., et al. Intravesical bacillus Calmette-Guerin for the treatment of superficial bladder cancer in renal transplant patients. Transplantation 76 (2003) 1514
12. Herr H.W., and Dalbagni G. Defining bacillus Calmette-Guerin refractory superficial bladder tumors. J Urol 169 (2003) 1706
13. McKhann C.F., Hendrickson C.G., Spitler L.E., Gunnarsson A., Banerjee D., and Nelson W.R. Immunotherapy of melanoma with BCG. two fatalities following intralesional injection. Cancer 35 (1975) 514
14. Aungst C.W., Sokal J.E., and Jager B.V. Complications of BCG vaccination in neoplastic disease. Ann Intern Med 82 (1975) 666
15. Sparks F.C., Silverstein M.J., Hunt J.S., Haskell C.M., Pilch Y.H., and Morton D.L. Complications of BCG immunotherapy in patients with cancer. N Engl J Med 289 (1973) 827
16. Amene P.C. Activation of pulmonary tuberculosis following intralesional corticosteroids. Arch Dermatol 119 (1983) 361
17. Miyaura H., and Iwata M. Direct and indirect inhibition of Th1 development by progesterone and glucocorticoids. J Immunol 168 (2002) 1087
18. Cisneros J.R., and Murray K.M. Corticosteroids in tuberculosis. Ann Pharmacother 30 (1996) 1298
19. Haanaes O.C., and Bergmann A. Tuberculosis emerging in patients treated with corticosteroids. Eur J Respir Dis 64 (1983) 294
20. Millar J.W., and Horne N.W. Tuberculosis in immunosuppressed patients. Lancet 1 (1979) 1176
21. Bahceciler N.N., Nuhoglu Y., Nursoy M.A., Kodalli N., Barlan I.B., and Basaran M.M. Inhaled corticosteroid therapy is safe in tuberculin-positive asthmatic children. Pediatr Infect Dis J 19 (2000) 215